Laurus Labs Q2 FY27 Profit Jumps 126% to ₹441 Crore as CDMO Revenue Surges 75%; Picks Up 60% Stake in Canada’s Galenvs

Laurus Labs reported Q2 FY27 net profit of ₹441 crore, up 126%, on revenue of ₹2,206 crore, as CDMO revenue rose 75% to ₹904 crore and EBITDA margin widened to 34.5%. The Hyderabad drugmaker also agreed to take a 60% stake in Montreal-based Galenvs Sciences to deepen its oligonucleotide capabilities.